ALTA2618 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment, ALTA2618, for individuals with advanced solid tumors that have a specific genetic change called the AKT1 E17K mutation. The main goal is to determine if the treatment is safe and well-tolerated. It targets those with tumors that cannot be surgically removed or have spread, and who have not responded to other treatments. Participants must be able to take oral medications and should not have certain other genetic changes. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that ALTA2618 is likely to be safe for humans?
Research has shown that ALTA2618 could be a promising treatment for some advanced cancers. It targets a specific change in cancer cells called the AKT1 E17K mutation, present in some tumors. Early results suggest that ALTA2618 is generally safe as a once-daily pill, with most people not experiencing serious side effects.
Studies have demonstrated positive results in how the body absorbs and uses ALTA2618, which is crucial for effectively reaching and impacting cancer cells. Although these findings are promising, ALTA2618 remains in the early stages of human testing. Researchers are currently focusing on its safety and are closely monitoring for any side effects. While there is some uncertainty with any new treatment, the safety of ALTA2618 appears promising so far.12345Why do researchers think this study treatment might be promising?
ALTA2618 is unique because it targets cancer cells with a novel mechanism of action that is different from traditional chemotherapy and radiation treatments. Unlike standard treatments that often affect both healthy and cancerous cells, ALTA2618 is designed to specifically disrupt cancer cell growth, potentially offering a more precise and less toxic option. Researchers are excited about ALTA2618 because it represents a new class of targeted therapy, which could lead to improved outcomes and fewer side effects for patients battling cancer.
What evidence suggests that ALTA2618 might be an effective treatment for advanced solid tumors?
Studies have shown that ALTA2618 effectively blocks a specific change in cancer cells called AKT1 E17K. This means it targets and stops this altered protein, which often promotes the growth of certain advanced solid tumors. ALTA2618, the investigational treatment in this trial, demonstrated promising results in early tests, with good drug levels in the body and good tolerance when taken once daily by mouth. These early findings suggest that ALTA2618 could be effective for patients with cancers driven by the AKT1 E17K mutation.23456
Who Is on the Research Team?
Study Medical Director
Principal Investigator
Alterome Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have a specific mutation called AKT1 E17K. It's open to those who haven't had success with previous treatments or for whom no suitable alternatives exist.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive ALTA2618 at increasing doses to determine the maximum tolerated dose
Dose Expansion
Participants receive ALTA2618 at the determined dose to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ALTA2618
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alterome Therapeutics, Inc.
Lead Sponsor